So-Young International Q2 2024 Earnings Call Transcript

Quartr
Provided by Quartr
August 23, 2024

There are 6 speakers on the call.

Operator

Ladies and gentlemen, thank you for standing by for Sohyoung's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen only mode. After management gives their prepared remarks, there will be a question and answer session. As a reminder, today's conference call is being recorded. I would now like to turn the conference over to your host for today's call, Ms.

Operator

Mona Chow. Please go ahead, Ms. Mona.

Speaker 1

Thank you, operator, and thank you, everyone, for joining Solium's Q2 2024 Earnings Conference Call. Joining me today on the call is Mr. Xin Jin, our Co Founder, Chairman and CEO and Mr. Nick Zhao, CFO. Please note that the discussion today will contain forward looking statements made under the Safe Harbor provisions of the U.

Speaker 1

S. Private Securities and the Litigation Reform Act of 1995. Forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include, but are not limited to, those outlined in our public filings with SEC, including our annual report on Form 20 F. Sohyeon does not undertake any obligation to update any forward looking statements, except as required under applicable law.

Speaker 1

At this time, I'd like to turn the call over to Mr. Xin Jin. Hello, everyone. Welcome to today's earnings call. Our performance during the Q2 was solid with total revenue of RMB407,400,000, excluding the top end of our guidance.

Speaker 1

Non GAAP net profit was RMB22.2 million, up 43.1 percent year over year, showcasing our high quality growth at the effectiveness of industry integration. We capitalized on industry trades, execute on our strategy and made impressive progress during the quarter. Specifically, our new businesses segments continue to grow rapidly with revenue from the sales of medical products and maintenance services reaching RMB106 1,000,000, up 22.6% year over year. Product shipments in our upstream supply chain business increased as our chain of clinics expanded, both contributing significantly to growth. We are the only platform covering the upstream, midstream and downstream segments of the entire aesthetic medical industry and are leading the industry into a new era of high quality and sustainable development.

Speaker 1

Leveraging the synergies created by the vertical integration, we are enhancing industry transparency and operational efficiency across the value chain. This closely aligns the industry value chain with involving consumer needs, ensures a diverse range of high quality and affordable products, optimize the customer experience and redefine standards for medical aesthetic services. We continue to drive high quality development in our parts segment and strengthen our competitive advantage in the mid to high end market by refining operations and deploying target user subsidies. With client demand for premium customized products growing, we adjust our strategy and upgraded SKUs, ensuring their authenticity and further enrich the categories offered by our leading partner institutions. We also strengthened support for high quality institutional partners by integrating our POP business with our child clinics to create deeper and greater synergies, enabling us to better meet the evolving and diverse medical aesthetic needs of mid to high end users.

Speaker 1

In the Q2, GM Way from medical aesthetic Products and Services reached RMB428 1,000,000 over 230,000 verified orders, up around 70% and 8%, respectively. We continue to optimize our traffic acquisition strategy by reallocating budget away from low ROI online channels to our private domains. Refining multichannel private domain operations allows us to cultivate and retain a target user base and improve user engagement and monetization efficiency. In the Q2, the use of private domains reached 810,000, up 14% quarter over quarter. Let's move on to Sohuang Province.

Speaker 1

Currently, we have opened 14 clinics in prime commercial areas in 8 core cities, including Beijing, Shanghai, Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing and Changsha. All of these clinics are fully operational and performing in line with expectations. Leveraging our strong user base, the reputational strength of our brand and standardized fulfillment capabilities, the number of verified customers increased by 85% quarter over quarter. The repeat purchase rate exceeded 50% and customer satisfaction improved to reach an impressive 4.97 out of 5. We've also achieved solid operational efficiencies.

Speaker 1

For example, our Beijing clinics generated revenue of CNY6.2 million in due with pretax profit of CNY1.3 million and a profit margin of around 20%. The repeat perchance rate hit 67%, higher than the industry average. Notably, both unit area efficiency and monthly revenue per doctor outperformed traditional clinics. The experience we have accumulated from this provide us with valuable insights that we will apply to other new clinics to accelerate their growth. We are very optimistic about the future of light medical aesthetic clinics and plan to begin franchising our chain of clinics in the second half of this year in order to rapidly expand our footprint by replicating this proven standardized model in the target cities.

Speaker 1

Lastly, I will provide updates on our supply chain business. Leveraging our brand's extensive consumer behavior data and experience team, we are building 4 category upstream medical aesthetic manufacturing capabilities for our broader ecosystem. With over a decade of operations, we have accumulated a wealth of consumer behavior data and user demand insights, laying a solid foundation development and customization of our products. In addition, leveraging our extensive institutional coverage and strong customer marketing capabilities, we are able to rapidly strengthen the competitiveness of new products using our clinics to ensure a steady stream of sales. Our core team is composed of professionals from top domestic and international manufacturers, each possessing an average of 5 to 10 years of industry experience and strong expertise in product selection and sales.

Speaker 1

In the second half of the year, we will continue to expand this team with a goal of reaching 100 members by the end of the year. Additionally, we've seen a continuous increase in shipments of Trulift, our newly launched non surgical anti aging ultra styled device, reflecting its strong potential to be a market hit. Meanwhile, the Korea brand, Elasti, has maintained strong growth momentum, with 2nd quarter shipments exceeding 40,000 units, up 76% quarter over quarter and 130% year over year. Revenue from the sales of injectables grew by 65% quarter over quarter and 170% year over year. As of the Q2 of 2024, we partnered with 7 18 institutions for the sales of injectables.

Speaker 1

Despite the soft recovery in conception as the macroeconomic challenge over the near term, We believe that the Chinese medical aesthetic market that still has enormous potential in the long term. As the industry begins reshuffling and enters a period of consolidation, leading brands like Sohyang with a unique ecosystem and full category advantage are well positioned to capitalize on the new opportunities, expand their market share and growth potential and solidify their position as market leaders. We believe our pulp business is ideally suited to meet demands for non standardized treatments, while our chain clinics can service standardized treatments. Supporting both of these businesses with a steady stream of exclusive products is our upstream business, which will also benefit from 2C and 2B opportunities and guaranteed sales offered by both downstream businesses. Combined, these three business segments create enormous synergies and form our area triangle.

Speaker 1

We strongly believe that vertically integrating the industry value chain will drive innovation, effectively ensure the quality of services and open up new growth opportunities for Sohuang going forward. I'll let our CFO, Nick, take over now to go through the Q2's financial results. After that, we'll open up for questions.

Speaker 2

Hello. This is Nick. Please be reminded that our earnings quoted here will be in RMB. Please also refer to our earnings release for detailed information of our comparative financial performances on a year over year basis. Total revenues during the quarter were RMB407.4 million, down 1.1% year over year, exceeding the high end of our guidance on the back of a 22.6% year over year increase in sales of medical products and maintenance services.

Speaker 2

Information services and other revenues were down 6.6 percent year over year, primarily due to a decrease in the number of medical service providers subscribing to information services in our platform. Reservation services revenues decreased 16.9 percent year over year to RMB22.4 million, primarily due to policy changes for commission rates and subsidies. Cost of revenues were RMB155.1 million, up 3.1% year over year, primarily due to an increase in costs associated with the sales of cosmetic products. Within cost of revenues, cost of services and others were RMB101.9 million, down 4.4% year over year, primarily due to a decrease in costs associated with Sohuang Prime. Cost of medical products sold and management services were RMB53.2 million, up 21.3% year over year, primarily due to an increase in costs associated with the sales of cosmetic products.

Speaker 2

Total operating expenses were RMB245.6 million, down 13% year over year. Sales and marketing expenses were RMB132.3 million, down 4.1% year over year, primarily due to a decrease in expenses associated with branding and user acquisition activities. G and A expenses were RMB70.8 million, down 23.3% year over year, primarily due to decreases in share based compensation expenses and the professional consulting fees. R and D expenses were RMB42.5 million, down 18.5 percent year over year, primarily attributable to improvements in staff efficiency. Income tax benefits were RMB2.6 million compared with income tax benefit of RMB0.8 million in the same period of 2023.

Speaker 2

Net income attributable to Sohuang was RMB18.9 million compared with a net loss of RMB2.6 million during the same period last year. Non GAAP net income attributable to Sohuang was RMB22.2 million compared with RMB15.5 million in the same period of 2023. Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.18 and RMB0.18, respectively, compared with basic and diluted losses per ADS attributable to ordinary shareholders of RMB0.02 and RMB0.02, respectively, during the same period of 2023. We have maintained a robust cash position with cash and cash equivalents, restricted cash and term deposits, term deposits and short term investments totaling RMB1.25 billion as of June 30, 2024. Moving to our outlook.

Speaker 2

Given the relatively soft macro conditions, especially with respect to discretionary spending, for the Q3 of 2024, we expect total revenues to be between RMB350 1,000,000 and RMB370 1,000,000. This outlook also takes into account the uncertainties of the pace of a clinic opening and ramping up. As we are in the early stage of our clinic expansion and our business transformation, that being said, we are confident our strategic initiatives integrating the upstream and downstream of the aesthetic medical industry value chain will ideally position us for our long term growth. Their initiatives will enable us to capture a significant larger share of the market and establish a solid foundation of profitability. As our clinics mature and market conditions stabilize, we expect our financial performance to gradually improve.

Speaker 2

This concludes our key remarks. I will now turn over to the call to the operator and open the call for Q and A. Operator, we are ready to take questions. Thank you.

Operator

We will now begin the question and answer And the first question will come from Chloe Wei with CICC. Please go ahead.

Speaker 3

So let me translate myself. Firstly, congratulations on the solid results. The revenue continued to exceed the high end and really strong bottom line. And my question is about the overall trend. So entering second half of this year, we have seen signs of slowdown in most consuming companies guidance, say the online platforms, tourism and etcetera.

Speaker 3

So I understand that's mostly due to the macro headwind, but can management share more color on the trends we have seen in July August from the consumers and also from advertisers side? And looking into the second half, are there anything we would like to share with the market about how we plan to adapt to the new changes? Thanks.

Speaker 1

The current state of the medical aesthetic industry isn't quite where we thought it would be at the beginning of the year. According to data from the MBS, the retail sales of consumer goods in China increased by 3.7% year over year in the 1st 6 months of 2024, a deceleration compared to the Q1 of 2024 and the last quarter of 2023. Despite weak consumer confidence and discretionary spending, the medical aesthetic market continues to grow and offer significant structural opportunities. The market share of Light Medical Aesthetic Services is expanding, driven by strong consumer demand for minimally invoices and convenient services. Meanwhile, the upstream supply chain is experiencing a surge in growth, fueled by innovations and supply chain optimizations that are propelling the industry's overall advancement.

Speaker 1

Our industry research highlights 2 key forecasts that will shape the future of the industry. First, we expect to see the standardization of light medical aesthetic services gain momentum. This will lead to emergence of large chain brands and enhanced market norms and efficiency, resulting in a more mature sector. 2nd, over the next 4 to 5 years, we anticipate that leading trends will dominate the market, significantly accelerating this trade concentration. As top rise capture larger share of market, new opportunities will be created for investors and entrepreneurs to capitalize on this trade.

Speaker 1

We plan to begin franchising our chain of clinics in the second half of the year. This will not only contribute to the industry's expansion, but also position us for success in rapidly evolving market. Thank you.

Operator

The next question will come from Nelson Cheung with Citibank. Please go ahead.

Speaker 4

My question is regarding the pulp business and wondering what would be the company's outlook on the positioning of the pulp business in your future development? And are there any new business strategy that can be shared with us?

Speaker 5

Thank

Operator

you.

Speaker 1

The Pop business remains a vital component of our growth strategy and we will continue to focus on its development. As we've said before, we believe that Chinese medical aesthetic market will become increasingly polarized. Consumer spending on standardized treatment is becoming more value driven, while spending on non standardized treatment is becoming more selective, with consumers willing to pay a premium for the highest quality care. To adapt to this market landscape, our strategy is twofold. 1, for standardized treatment, we leverage the strength and service quality of our chain clinics to meet client demand.

Speaker 1

And 2, for non standardized treatment, we will rely on diverse array of treatments that our pulp business facilitates to satisfy various needs. We are moving towards a curated model just like Costco and Sam's Club by selecting high quality institutions, leading doctors and premium SKUs in each vertical, we aim to simplify customer decision making, increase SKU transaction value and ultimately strengthen our control over the supply side to enhance our pricing power. Additionally, for partners who are strong technically but lack operational expertise, we offer comprehensive operational services management. A prime example of this is our master injector team, which consists of injectable specialists, each boasting an impressive track record of 10,000 treatments. We provide them with online operational support, enabling them to focus exclusively on delivering service to customers.

Speaker 1

Demand for this service has grown rapidly and received widespread positive feedback. Going forward, our chain of clinics will create strong synergies with our POP business as it grows to scale by identifying non standardized treatments in demand by customers of our chain of clinics and promoting select high quality institutions and doctors from POP. We are maximizing both customer satisfaction and commercial value. Thank you.

Operator

The next question will come from Patrick He with Citic Securities. Please go ahead.

Speaker 5

Okay. So let me just briefly translate for myself. Thank you for management and thank you for taking my question. I'm Chad Petri from Citi Securities. So I'm just wondering more questions about the clinical chain business.

Speaker 5

So I'm wondering what factors might constrain the speed of the clinical chain expansion? And what are the unique advantages that Zohya have in addressing these constraints so that we can addressing these constraints more effectively than our competitors? And additionally, what are the current operating metrics for the chain of clinics? And for example, if our clinics have reached breakeven and what is your future business plans? Thank you very much.

Speaker 1

In general, factors such as site selection, furnishing and renovation, license application, staff recruitment, marketing and operational costs can impact how quickly new clinics can open up. Having said that, we've significantly improved new clinic opening efficiency by creating respective SOPs and implementing effective process management. This has helped us cut down the average time required to open up new clinic from about 5 months early to around 3 months now. However, we believe the following factors are what truly determine how quickly we can sell our chain of clinics. 1, the ability to acquire customers.

Speaker 1

If we cannot guarantee that, we'll simply incur losses. 2, the ability to recruit a sufficient number of leading doctors and specialists. 3, the strength of our supply chain, which is key to offering products at competitive price while keeping profit margins 4, sufficient capital as the initial investment for each new clinic can cost 1,000,000 of rmb and 5, the ability to obtain the necessary license. We are already positioned to address each of these factors. We have solid customer acquisition capabilities that leverage our strong brand recognition as the expensive user base already on our platform.

Speaker 1

This is further enhanced by our contact and online marketing capabilities. Our strong brand recognition, scale of our business and compliance with regulations give us a significant advantage when recruiting professionals when compared to small and medium sized institutions. On the supply chain side, our initiatives over the past few years are already beginning to yield positive results. As more of our products receive certification, we expect our competitive advantage in this vertical to positively impact our financial performance more meaningfully. By continuously enhancing our Midu platform capabilities through the Sogouan Prime program over the past year, we are able to ensure standardized management across multiple clinics in different regions.

Speaker 1

We believe that the key to standardized management lies in the breadth and depth of digitalization, an area where we have a natural advantage as an Internet company. We have ample capital to deploy in new clinics as well. The franchise model that are launching in the second half of the year also allow us to expand without the need to invest our own capital. In terms of license applications, aside from Beijing and Shanghai, obtaining license in other regions of China is relatively simple and fast. Having already set up clinics nationwide, we have accumulated experience in this area.

Speaker 1

As of today's earnings call, we have opened 14 clinics in prime commercial areas. All of these clinics are fully operational and performing in line with our expectations. Our Beijing clinic has been operational for 15 months and has already become profitable, recouping its initial investment. Among the other clinics, 3 have been operational for 5 months with the remaining ten for less than 3 months. They are following a similar growth trajectory, but will require a little more time to reach breakeven.

Speaker 1

To provide some more context, our clinics typically follow a well defined growth curve. They generally go through a 3 month trial period followed by 9 months of accelerated growth. Maturities usually reached after about 12 months of operations. For example, our Beijing clinic began trial operations in May and officially opened in August last year. Since then, revenue has grown to RMB6.2 million due this year with pretax profit of RMB1.3 million and a profit margin of around 20%.

Speaker 1

This outstanding performance validates the effectiveness of our site selection, clinic opening and operational strategies, providing valuable insights that we will apply to other new clinics to accelerate their growth. By leveraging our Mido platform, we have reduced overall costs while ensuring standardized services delivery, allowing us to outperform other institutions. In the future, as procurement volume and use our self branded products increase, cost across our chain of clinics will gradually fall and profit margin will increase. Looking ahead, our future business plans are centered on expanding our clinics across target cities with a focus on increasing the density of clinics within each city. By the end of 2024, we plan to open over 20 clinics.

Speaker 1

In the second half of the year, we will also launch our franchise model with external partners to leverage our self operated clinics as training centers and flagship clinics. This will enable us to standardize and scale rapidly. We expect a significant year over year increase in the number of clinics, which will not only strengthen our market position, but also create new opportunities for revenue growth.

Operator

Thank you. The next question will come from Joey Huang with Jefferies. Please go ahead.

Speaker 2

So

Speaker 1

perspective regarding the strategic positioning and the business plan for the upstream sector this year? Thank you. Unlike traditional manufacturers that rely on linear R and D to production to sales model, we capitalize our unique ecosystem and for category advantage to create synergies with our existing business lines. The integrated approach allow us to amplify the strength of our brand reputation among customers and network coverage through institutional partners. As a result, we can rapidly build market competitiveness for new products and achieve customer targeting through our app and media metrics, while using our clinics to ensure a steady stream of sales, a capability that sets us apart in the industry.

Speaker 1

For example, Tru Lift, our non surgical anti aging ultrasound device generated tremendous pre order volumes and saw sales volumes beyond expectations when it launched not long ago. This performance showcase its potential to become a market hit and the capabilities of our team. Similarly, sales of the Korea brand, Elasti, continue to grow. In addition, we have been actively expanding our pipelines with high growth potential. Our roadmap is robust with 2 new products ready for launch next year and 3 more in 2026, all targeting popular segments of injectables and energy based devices.

Speaker 1

We are confident these products will make significant contributions to revenue growth. Leveraging our broad extensive consumer behavior data and experience team, we are building full category upstream capabilities for our broader ecosystem. In the second half of the year, we will continue to expand our team, which is currently composed of seasoned experts from a leading domestic and international manufacturers. We aim to grow this team to a total of 100 members by the end of the year. Thank you.

Operator

Your next question will come from Ivy Lee with Haitong Securities. Please go ahead.

Speaker 1

With current gross margins around 60%, can you please provide some insight into the expectation for the gross margin going forward? Thank you.

Speaker 2

Thanks for your question. Over the near term, macroeconomic risks such as slowing global growth and inflationary pressures continue to weigh on consumer sentiment. As a result, consumer willingness and capability to spend may be constrained, increasing market uncertainty. This is reflected in our Q3 revenue guidance. As we transform our business beyond the POP business, our revenue structure is undergoing a shift alongside, which is impacting gross margin levels.

Speaker 2

While our traditional information and resolution services continue to enjoy high gross margins. The increasing share of medical product sales, which have stable but lower margins, is affecting our overall margin profile. Furthermore, our chain of clinics, which is still in its early stages, has seen gross margin temporarily impacted by promotional activities. In the short term, we expect gross margins will continue to be impacted by the expansion of our chain of clinics and medical product sales. However, as our upstream supply chain capabilities strengthen and operation across our clinics mature, we will anticipate a corresponding improvement in gross margin.

Speaker 2

Additionally, the introduction of our franchise model is expected to support gross margin through greater economies of scale, optimizing our profit structure even further. Thank you.

Operator

This concludes our question and answer session as well as our conference call for today. Thank you for attending today's presentation. You may now disconnect.

Powered by Quartr

Key Takeaways

  • In Q2 Sohyoung reported total revenue of RMB407.4 million (down 1.1% year-over-year but above guidance) and achieved a non-GAAP net profit of RMB22.2 million, up 43.1% year-over-year, compared with a net loss in the same period last year.
  • The medical products and maintenance services segment grew 22.6% year-over-year to RMB106.1 million, with injectables sales up 170% year-over-year and shipments of the Korea brand Elasti rising 130% year-over-year.
  • Sohyoung has opened 14 light-medical aesthetic clinics in 8 major cities, driving an 85% quarter-over-quarter increase in verified customers, a >50% repeat purchase rate and a 20% profit margin at its Beijing location, and plans to begin franchising in H2.
  • The company’s fully vertically integrated model—covering upstream manufacturing, midstream distribution and downstream services—is leveraging synergies to boost transparency, operational efficiency and product innovation, and its upstream team will grow to 100 members by year-end.
  • For Q3, Sohyoung expects revenue of RMB350 million–RMB370 million amid macro uncertainties, but remains confident that clinic maturation and integration will drive long-term growth and margin improvement.
AI Generated. May Contain Errors.
Earnings Conference Call
So-Young International Q2 2024
00:00 / 00:00